Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 6
1997 5
1998 4
2000 1
2002 7
2003 7
2004 4
2005 12
2006 47
2007 72
2008 88
2009 90
2010 81
2011 87
2012 123
2013 98
2014 88
2015 48
2016 53
2017 67
2018 88
2019 104
2020 129
2021 162
2022 144
2023 93
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

1,303 results

Results by year

Filters applied: . Clear all
Page 1
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF. Mori K, et al. Among authors: karakiewicz pi. BJU Int. 2022 Apr;129(4):423-433. doi: 10.1111/bju.15507. Epub 2021 Jul 21. BJU Int. 2022. PMID: 34171173 Free PMC article. Review.
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: karakiewicz pi. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):139-148. doi: 10.1038/s41391-021-00395-4. Epub 2021 May 30. Prostate Cancer Prostatic Dis. 2022. PMID: 34054128 Free PMC article. Review.
Reply by Authors.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: karakiewicz pi. J Urol. 2021 Jul;206(1):79. doi: 10.1097/JU.0000000000001695.03. Epub 2021 Apr 6. J Urol. 2021. PMID: 33820427 No abstract available.
AUTHOR REPLY.
Knipper S, Graefen M, Karakiewicz PI. Knipper S, et al. Among authors: karakiewicz pi. Urology. 2019 Nov;133:142-143. doi: 10.1016/j.urology.2019.05.055. Urology. 2019. PMID: 31706414 No abstract available.
Editorial Comment.
Karakiewicz PI. Karakiewicz PI. J Urol. 2019 Sep;202(3):531. doi: 10.1097/01.JU.0000569232.25218.7c. Epub 2019 Aug 8. J Urol. 2019. PMID: 31192750 No abstract available.
Intermediate-risk Prostate Cancer: Stratification and Management.
Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV. Preisser F, et al. Among authors: karakiewicz pi. Eur Urol Oncol. 2020 Jun;3(3):270-280. doi: 10.1016/j.euo.2020.03.002. Epub 2020 Apr 14. Eur Urol Oncol. 2020. PMID: 32303478 Review.
A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Motlagh RS, Laukhtina E, Rajwa P, Deimling MV, Bianchi A, Pallauf M, Majdoub M, Pradere B, Moschini M, Karakiewicz PI, Teoh JY, Miki J, Kimura T, Shariat SF. Yanagisawa T, et al. Among authors: karakiewicz pi. Eur Urol Focus. 2023 May;9(3):463-479. doi: 10.1016/j.euf.2022.12.003. Epub 2022 Dec 12. Eur Urol Focus. 2023. PMID: 36517409 Free article. Review.
1,303 results